The administration of rituximab, targeting B cells to mitigate autoantibody production against ADAMTS13, featured prominently in her management, aligning with its recognized role in refractory or relapsing TTP cases. This evidence concerns the gene ADAMTS13 and thrombotic thrombocytopenic purpura.